Literature DB >> 20123472

Psychiatric symptoms and disorders in phenylketonuria.

V L Brumm1, D Bilder, S E Waisbren.   

Abstract

Psychological and psychiatric problems are well documented across the lifespan of individuals with early-treated phenylketonuria (PKU). Early-treated children and adolescents tend to display attentional problems, school problems, lower achievement motivation, decreased social competence, decreased autonomy, and low-self-esteem. As they enter adulthood, early-treated individuals may carry forward low self-esteem and lack of autonomy but also tend to develop depressed mood, generalized anxiety, phobias, decreased positive emotions, social maturity deficits, and social isolation. The correlation between level of metabolic control and severity of symptoms suggests a biological basis of psychiatric dysfunction. Additionally, psychosocial factors such as the burden of living with a chronic illness may contribute to psychological and psychiatric outcomes in PKU. The lack of a PKU-specific psychiatric phenotype combined with the observation that not everyone with PKU is affected highlights the complexity of the problem. More research on psychiatric and psychological outcomes in PKU is required. Of particular importance is the routine monitoring of emotional, behavioral, and psychosocial symptoms in individuals with this metabolic disorder. Longitudinal studies are required to evaluate the impact of new and emerging therapies on psychiatric and psychosocial functioning in PKU. Unidentified or untreated emotional and behavioral symptoms may have a significant, lifelong impact on the quality of life and social status of patients. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20123472     DOI: 10.1016/j.ymgme.2009.10.182

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  43 in total

1.  Neurobehavioral problems associated with phenylketonuria.

Authors:  Steven D Targum; William Lang
Journal:  Psychiatry (Edgmont)       Date:  2010-12

2.  Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria.

Authors:  Oriane Leuret; Magalie Barth; Alice Kuster; Didier Eyer; Loïc de Parscau; Sylvie Odent; Brigitte Gilbert-Dussardier; François Feillet; François Labarthe
Journal:  J Inherit Metab Dis       Date:  2012-03-03       Impact factor: 4.982

3.  Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience.

Authors:  Stephanie J DeWard; Ashley Wilson; Heather Bausell; Ashley S Volz; Kimberly Mooney
Journal:  J Genet Couns       Date:  2013-09-08       Impact factor: 2.537

4.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

Review 5.  Inborn errors of metabolism associated with psychosis: literature review and case-control study using exome data from 5090 adult individuals.

Authors:  Yannis J Trakadis; Vanessa Fulginiti; Mark Walterfang
Journal:  J Inherit Metab Dis       Date:  2017-02-16       Impact factor: 4.982

6.  Developmental Trajectories of Executive and Verbal Processes in Children with Phenylketonuria.

Authors:  Zoë W Hawks; Michael J Strube; Neco X Johnson; Dorothy K Grange; Desirée A White
Journal:  Dev Neuropsychol       Date:  2018-02-12       Impact factor: 2.253

7.  Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life.

Authors:  B Ziesch; J Weigel; A Thiele; U Mütze; C Rohde; U Ceglarek; J Thiery; W Kiess; S Beblo
Journal:  J Inherit Metab Dis       Date:  2012-03-06       Impact factor: 4.982

8.  Micronutrients, Essential Fatty Acids and Bone Health in Phenylketonuria.

Authors:  Serwet Demirdas; Francjan J van Spronsen; Carla E M Hollak; J Hanneke van der Lee; Peter H Bisschop; Fred M Vaz; Nienke M Ter Horst; M Estela Rubio-Gozalbo; Annet M Bosch
Journal:  Ann Nutr Metab       Date:  2017-03-24       Impact factor: 3.374

9.  Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Authors:  Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White
Journal:  Mol Genet Metab       Date:  2014-11-13       Impact factor: 4.797

Review 10.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.